SEC Filing Summary: Access Pharmaceuticals, Inc. (10-Q)
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended September 30, 2009. Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company focused on nanopolymer chemistry and drug delivery technologies. The company operates with one FDA-approved product, MuGard (for oral mucositis), and a pipeline including ProLindac (Phase 2 cancer treatment), Thiarabine (Phase 1/2), and preclinical oral delivery technologies. The financial statements reflect the combined operations of Access and MacroChem Corporation, acquired on February 25, 2009, under a pooling-of-interest method due to common control.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2009 | Nine Months Ended Sep 30, 2009 |
|---|---|---|
| Total Revenues | $144,000 | $248,000 |
| Net Loss (Common Stockholders) | $(4,542,000) | $(9,802,000) |
| Loss Per Share (Basic/Diluted) | $(0.37) | $(0.86) |
| Cash and Cash Equivalents | $1,672,000 | $1,672,000 (Ending Balance) |
| Working Capital Deficit | $(6,252,000) | $(6,252,000) |
| Accumulated Deficit | $(245,787,000) | $(245,787,000) |
| Long-Term Debt | $5,500,000 | $5,500,000 |
| Net Cash Burn Rate | ~$115,000/month | ~$115,000/month |
Material Changes vs. Prior Period
- Revenue Growth: Licensing revenue increased to $124,000 in Q3 2009 from $38,000 in Q3 2008. Royalties of $20,000 were recognized in Q3 2009, compared to none in the prior year.
- Expense Reduction: Total operating expenses decreased significantly for the nine-month period ($8.2M in 2009 vs. $29.2M in 2008). This $20.9M decrease is primarily attributed to the elimination of one-time non-cash in-process R&D charges from prior acquisitions (Somanta and Virium) totaling ~$18.5M in 2008.
- Loss Reduction: Net loss allocable to common stockholders decreased to $9.8M for the nine months ended Sep 30, 2009, compared to $32.2M in the same period in 2008.
- Acquisition Impact: The acquisition of MacroChem was completed in February 2009. MacroChem debt was exchanged for common stock, reducing interest expense.
Outlook, Risks, and Management Commentary
- Liquidity and Going Concern: Management states that current capital resources are adequate to fund operations only into the first quarter of 2010. The company explicitly states it does not have enough capital to achieve long-term goals and must seek additional financing within the next twelve months. Failure to do so jeopardizes the ability to continue as a going concern.
- Internal Controls: The company disclosed a material weakness in internal control over financial reporting. Disclosure controls were deemed ineffective due to a lack of segregation of duties, as all financial reporting is performed by the CFO without sufficient accounting staff.
- Debt and Dividends: The company has accrued $2,294,000 in preferred stock dividends and $1,153,000 in liquidated damages related to registration statement delays. A $5.5M convertible note is outstanding, with interest due in September 2009 currently under negotiation for a payment plan.
- Operational Updates: Agreements were signed for the North American launch of MuGard with iMedicor and manufacturing with Accupac. Clinical trials for ProLindac are ongoing in France.
Investor Verification Checklist
- Cash Runway: Verify the timeline for securing additional financing, as the company projects insolvency by Q1 2010 without new capital.
- Debt Obligations: Confirm the status of the $5.5M convertible note interest payment and the $1.15M accrued liquidated damages.
- Internal Controls: Assess the remediation plan for the material weakness in financial reporting and the lack of accounting staff.
- Revenue Recognition: Review the terms of licensing agreements with SpePharm, RHEI, JCOM, and ASK to understand the sustainability of the $248k revenue stream.
- Dilution Risk: Monitor equity issuances, as the company has issued significant shares for services, dividends, and debt conversion, increasing the share count to over 13 million.